Latest On Next Science Limited (NXSCF):
| Date/Time | Type | Description | Signal | Details |
|---|---|---|---|---|
| 2021-02-25 00:21 EST | Financials | Company financials have been released. | Neutral |  |
| 2020-12-04 06:24 EST | Financials | Company financials have been released. | Neutral | |
| 2020-11-27 00:43 EST | Financials | Company financials have been released. | Neutral | |
| 2020-10-08 21:05 EST | Financials | Company financials have been released. | Neutral | |
| 2020-10-04 15:23 EST | Financials | Company financials have been released. | Neutral | |
| 2020-09-26 16:37 EST | Financials | Company financials have been released. | Neutral | |
| 2020-09-17 09:16 EST | Financials | Company financials have been released. | Neutral | |
| 2020-08-27 19:14 EST | Financials | Company financials have been released. | Neutral | |
| 2020-08-14 12:42 EST | Financials | Company financials have been released. | Neutral | |
| 2020-08-06 16:24 EST | Financials | Company financials have been released. | Neutral | |
| 2020-08-04 19:41 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-31 12:04 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-31 04:31 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-30 20:40 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-30 08:29 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-30 00:47 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-28 16:12 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-27 16:22 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-23 21:12 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-09 12:33 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-09 07:32 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-02 23:35 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-01 20:12 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-01 04:03 EST | Financials | Company financials have been released. | Neutral | |
| 2020-06-25 07:25 EST | Financials | Company financials have been released. | Neutral | |
| 2020-06-19 16:02 EST | Financials | Company financials have been released. | Neutral | |
| 2020-06-14 08:14 EST | Financials | Company financials have been released. | Neutral | |
| 2020-06-12 09:47 EST | Financials | Company financials have been released. | Neutral | |
| 2020-06-07 19:47 EST | Financials | Company financials have been released. | Neutral | |
| 2020-06-05 15:34 EST | Financials | Company financials have been released. | Neutral | |
| 2020-06-03 19:25 EST | Financials | Company financials have been released. | Neutral | |
| 2020-05-27 08:51 EST | Financials | Company financials have been released. | Neutral | |
| 2020-05-21 04:38 EST | Financials | Company financials have been released. | Neutral | |
| 2020-05-14 03:52 EST | Financials | Company financials have been released. | Neutral | |
| 2020-05-07 11:36 EST | Financials | Company financials have been released. | Neutral | |
| 2020-05-07 03:54 EST | Financials | Company financials have been released. | Neutral | |
| 2020-05-06 09:16 EST | Financials | Company financials have been released. | Neutral | |
| 2020-05-02 23:43 EST | Financials | Company financials have been released. | Neutral | |
| 2020-05-01 20:01 EST | Financials | Company financials have been released. | Neutral | |
| 2020-04-30 07:30 EST | Financials | Company financials have been released. | Neutral | |
About Next Science Limited (NXSCF):
Next Science Limited, a medical technology company, researches, develops, and commercializes technologies to eradicate issues in human health caused by biofilms. It develops its products using its Xbio Technology platform. The company offers SurgX, an antimicrobial gel designed to reduce surgical site and post-surgical infections; and Bactisure, a surgical lavage that is used to remove debris, including microorganisms from wounds. It also provides BlastX, an antimicrobial wound gel that destroys bacteria within the gel and defends from recolonization while maintaining a moist wound environment. The company has strategic partnerships with Montana State University Center for Biofilm Engineering, Mayo Clinic, Texas Tech University, University of Florida, and Jacksonville Center for Clinical Research. Next Science Limited was founded in 2012 and is headquartered in Sydney, Australia.
General
- Name Next Science Limited
- Symbol NXSCF
- Type Common Stock
- Exchange PINK
- Currency USD
- Country USA
- SectorHealthcare
- IndustryDrug Manufacturers-Specialty & Generic
- Fiscal Year EndDecember
- Web URLhttp://www.nextscience.com
View More
Valuation
- Forward PE 120.48
- Price/Sales (Trailing 12 Mt.) 51.08
- Price/Book (Most Recent Quarter) 9.75
- Enterprise Value Revenue 36.62
View More
Financials
- Most Recent Quarter 2020-12-31
- Operating Margin -354%
- Return on Assets -33%
- Return on Equity -62%
- Revenue 3.44 million
- Earnings Per Share -$0.08
- Revenue Per Share $0.02
- Gross Profit 2.92 million
- Quarterly Earnings Growth 39.1%
View More
Highlights
- Market Capitalization 185.86 million
- EBITDA -13810177
- Book Value Per Share $0.14
View More
Share Statistics
- Shares Outstanding 194.2 million
- Shares Float 82.02 million
- % Held by Insiders 6258%
View More
Technicals
- 52 Week High $1.34
- 52 Week Low $0.58
- 50 Day Moving Average 0.95
- 200 Day Moving Average 0.94
View More
Dividends
- Dividend Date N/A
- ExDividend Date N/A
- Dividend Yield 0%
View More
Next Science Limited (NXSCF) Dividend Calendar:
| Ex-Dividend Date | Payment Date | Record Date | Declared Date | Amount |
|---|
Next Science Limited (NXSCF) Earnings History:
Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.
| Quarter Date | Report Date | Actual Revenue | Reported EPS | EPS Estimate | Deviation from Estimate |
|---|---|---|---|---|---|
| 2020-09-30 | 2020-12-31 | $N/A | -$0.01 | $0.00 | |
| 2020-06-30 | 2020-09-30 | $N/A | -$0.01 | $0.00 | |
| 2020-03-31 | 2020-06-30 | $N/A | -$0.02 | $0.00 | |
| 2019-12-31 | 2020-03-31 | $857815 | -$0.02 | $0.00 | |
| 2019-09-30 | 2019-12-31 | $857815 | -$0.02 | $0.00 | |
| 2019-06-30 | 2019-09-30 | $1.17 million | -$0.02 | $0.00 | |
| 2019-03-31 | 2019-06-30 | $1.17 million | -$0.03 | $0.00 | |
| 2018-12-31 | 2019-03-31 | -$0.03 | $0.00 | ||
| 2018-09-30 | 2018-12-31 | -$0.03 | $0.00 | ||
| 2018-06-30 | 2018-09-30 | $363781 | -$0.03 | $0.00 | |
| 2018-03-31 | 2018-06-30 | $363782 | -$0.03 | $0.00 | |
| 2017-12-31 | 2018-03-31 | -$0.03 | $0.00 |
Next Science Limited (NXSCF) Company Financial Statements:
Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.
Income Statement:
| Date | Dec 31 2020 | Sep 30 2020 | Jun 30 2020 | Mar 31 2020 | Dec 31 2019 |
|---|---|---|---|---|---|
| Research Development | N/A | N/A | N/A | N/A | 347606 |
| Income Before Tax | N/A | N/A | N/A | N/A | -3.89 million |
| Selling General Administrative | N/A | N/A | N/A | N/A | 3.28 million |
| Gross Profit | N/A | N/A | N/A | N/A | 772221 |
| Ebit | N/A | N/A | N/A | N/A | -3.08 million |
| Operating Income | N/A | N/A | N/A | N/A | -3.08 million |
| Income Tax Expense | N/A | N/A | N/A | N/A | N/A |
| Total Revenue | N/A | N/A | N/A | N/A | 857815 |
| Cost of Revenue | N/A | N/A | N/A | N/A | 85594 |
| Total Other Income Expense Net | N/A | N/A | N/A | N/A | -809545 |
| Net Income From Continuing Operations | N/A | N/A | N/A | N/A | -3.89 million |
| Net Income Applicable to Common Shares | -2.61 million | -2.61 million | -3.35 million | -3.35 million | -3.89 million |
Cash Flow:
| Date | Jun 30 2020 | Mar 31 2020 | Dec 31 2019 | Sep 30 2019 | Jun 30 2019 |
|---|---|---|---|---|---|
| Investments | N/A | N/A | N/A | N/A | N/A |
| Change to Liabilities | N/A | N/A | -109924 | -109924 | N/A |
| Total Cash Flow from Investing Activities | -226134 | -226134 | -467473 | -467473 | -336539 |
| Net Borrowings | -53691 | -53691 | -105167 | -105167 | 35399 |
| Total Cash Flow from Financial Activities | N/A | N/A | 52012 | 52012 | 11.79 million |
| Change to Operating Activities | N/A | N/A | -369918 | -369918 | -369918 |
| Change in Cash | N/A | N/A | -3.03 million | -3.03 million | 7.88 million |
| Total Cash from Operating Activities | -2.4 million | -2.4 million | -2.6 million | -2.6 million | -3.57 million |
| Depreciation | N/A | N/A | 121967 | 121967 | 107401 |
| Other Cash Flow from Investing Activities | N/A | N/A | N/A | N/A | N/A |
| Change to Inventory | N/A | N/A | -111547 | -111547 | -111547 |
| Change to Account Receivables | N/A | N/A | -289176 | -289176 | -289176 |
| Other Cash Flow from Financing Activities | N/A | N/A | 1829 | 1829 | -860829 |
| Change to Net Income | 778971 | 778971 | 1.88 million | 1.88 million | -409902 |
| Capital Expenditures | N/A | N/A | 139874 | 139874 | 47468 |
Balance Sheet:
| Date | Dec 31 2020 | Sep 30 2020 | Jun 30 2020 | Mar 31 2020 | Dec 31 2019 |
|---|---|---|---|---|---|
| Total Liabailities | N/A | N/A | N/A | N/A | 4.76 million |
| Total Stockholder Equity | N/A | N/A | N/A | N/A | 27.64 million |
| Other Current Liabilities | 2.4 million | 2.4 million | N/A | N/A | 535406.79 |
| Total Assets | N/A | N/A | N/A | N/A | 32.4 million |
| Common Stock | 101.28 million | 101.28 million | 90.77 million | 90.77 million | 90.69 million |
| Other Current Assets | N/A | N/A | N/A | N/A | 332504 |
| Retained Earnings | -41.1 million | -41.1 million | -35.88 million | -35.88 million | -41.66 million |
| Other Liabilities | 1.38 million | 1.38 million | 1.62 million | 1.62 million | 1.33 million |
| Other Assets | 1.41 million | 1.41 million | 36656 | 36656 | 1.32 million |
| Cash | N/A | N/A | N/A | N/A | 24.14 million |
| Total Current Liabilities | 3.23 million | 3.23 million | N/A | N/A | 2.45 million |
| Other Stockholder Equity | -41.27 million | -41.27 million | -42.16 million | -42.16 million | -42.15 million |
| Property, Plant & Equipment | 1.02 million | 1.02 million | 1.16 million | 1.16 million | 1.21 million |
| Total Current Assets | 20.25 million | 20.25 million | N/A | N/A | 27.52 million |
| Long Term Investments | N/A | N/A | N/A | N/A | N/A |
| Net Tangible Assets | 17.95 million | 17.95 million | 10.41 million | 10.41 million | 18.49 million |
| Short Term Investments | N/A | N/A | N/A | N/A | N/A |
| Long Term Debt | N/A | N/A | N/A | N/A | N/A |
| Inventory | 1.07 million | 1.07 million | N/A | N/A | 571453.04 |
| Accounts Payable | 571460 | 571460 | N/A | N/A | 896424.49 |
Next Science Limited (NXSCF) Chart:
Next Science Limited (NXSCF) News:
Below you will find a list of latest news for Next Science Limited (NXSCF) from major news sources. You can filter the results to only show news from a specific source.
No recent news available
Next Science Limited (NXSCF) Options:
A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.
| Expiration Date | Strike | Last Price | Type | Volume | Open Interest | Implied Volatility | In The Money | Change | Change Percent |
|---|
Next Science Limited (NXSCF) SEC Filings:
An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.
| Date | Form Type | Form Name | Link |
|---|